story of the week
Safety of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, HR+/HER2− Advanced or Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer
J. Clin. Oncol 2024 Sep 05;[EPub Ahead of Print], KL Jhaveri, MK Accordino, PL Bedard, A Cervantes, V Gambardella, E Hamilton, A Italiano, K Kalinsky, IE Krop, M Oliveira, P Schmid, C Saura, NC Turner, A Varga, S Cheeti, S Hilz, KE Hutchinson, Y Jin, S Royer-Joo, U Peters, N Shankar, JL Schutzman, D JuricFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.